-
平臺(tái)編號(hào)：bio-68565
-
國(guó)際編號(hào)：HB-9421?
-
細(xì)胞信息： CKMM 14.52
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
CKMM 14.52
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
器官來(lái)源：脾
ATCC Number：HB-9421?
是否是腫瘤細(xì)胞：0
物種來(lái)源：大鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1 kappa
規(guī)格：0.1ml Designations: CKMM 14.52
Depositors: ?Eastman-Kodak Co.
Isotype: IgG1 kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Organ: spleen
Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human CK-MM (creatine kinase - MM)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with human creatine kinase - MM.
Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
The antibody reacts preferentially with CK-MM, but cross-reacts with CK-MB.
Binding of the antibody inhibits the enzyme activity of both CK-MM and CK-MB.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml.
Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 21951: Daiss JL. Blend of monoclonal antibodies. US Patent 4,950,592 dated Aug 21 1990
數(shù)量：大量
器官來(lái)源：脾
ATCC Number：HB-9421?
是否是腫瘤細(xì)胞：0
物種來(lái)源：大鼠
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1 kappa
規(guī)格：0.1ml Designations: CKMM 14.52
Depositors: ?Eastman-Kodak Co.
Isotype: IgG1 kappa
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Organ: spleen
Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human CK-MM (creatine kinase - MM)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with human creatine kinase - MM.
Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
The antibody reacts preferentially with CK-MM, but cross-reacts with CK-MB.
Binding of the antibody inhibits the enzyme activity of both CK-MM and CK-MB.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml.
Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 21951: Daiss JL. Blend of monoclonal antibodies. US Patent 4,950,592 dated Aug 21 1990
